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This historic article review addressing several articles, in- 
cluding P. W. Wilson et al.'s seminal 1980 article on the 
Framingham Offspring Study, clearly demonstrates how the 
Framingham Heart Study was a true milestone in the 
history of cardiology. 
Prevalence of Coronary Heart Disease 
in the Framingham Offspring Study: 
Role of Lipoprotein Cholesterols 
by P. W. Wilson, R. J. Garrison, W. P. Castelli, 
M. Feinleib, P. M. McNamara, and W. B. Kannel (6) 
ABSTRACT 
Forty-three ofl,312 men aged35 to 54years in the Framing- 
ham Offspring Study had clinically recognized coronary heart 
disease at the initial examination. Twenty-six men in this 
group had previously had a myocardial infarction. Of 1,296 
women in the same age range, only 11 had coronary disease and 
3 a prior myocardial infarction. The prevalence of coronary 
/~eart disease in men was strongly associated with age, smoking, 
/.,igh density lipoprotein (HDL), low density lipoprotein (LDL) 
and total cholesterol using univariate analyses. When multivar- 
iate logistic regression analysis was used, age, smoking and 
HDL and LDL cholesterol retained their significant association 
with coronary heart disease. The total cholesterol/HDL choles- 
/,'rol ratio was also strongly associated with coronary heart 
disease in the multivariate analysis. It is concluded that both 
HDL and LDL cholesterol are strongly and independently 
associated with the prevalence of coronary heart disease, whereas 
the level of very low density lipoprotein cholesterol makes no 
statistically significant independent contribution. 
L)riginally published in American Journal of Cardiology, October 1980. 
Review 
In the late 1940% a longitudinal observational overview-- 
the Framingham Heart Study--was organized and funded 
by grants from the National Heart Institute (1). This study 
was launched after World War  II, when the alarming 
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prevalence of atherosclerotic vascular disease was appreci- 
ated, and its primary relation to sudden death, myocardial 
infarction and stroke recognized. From this realization came 
an understanding of the potential for the serious personal, 
economic and political consequences of atherosderotic ves- 
sel disease (ASVD) and the identification of ASVD as a 
50th Anniversary Historical Article 
INTRODUCTION 
In this edition of the Journal, we release the fifth in a series of 
reviews of influential articles that have been previously pub- 
fished in ACC journals, including the American Journal of 
Cardiology (from 1958 to 1982) and JACC (from 1983 to the 
present). The publication of these articles is only one aspect of 
the ACC's 50th anniversary commemoration, which highlights 
50 years of leadership in cardiovascular care and education. The 
articles are intended to encourage reflection on the remarkable 
progress made in cardiovascular medicine over time, as well as 
to acknowledge the amazing prescience of some early investi- 
gators in anticipating and, in many cases, later guiding devel- 
opments in their field. 
The working group responsible for selecting these articles and 
asking reviewers to write editorials solicited suggestions from 
the ACC's clinical committees and individual members. 
The group achieved consensus fairly easily, including whom the 
group should ask to prepare the accompanying editorials. We 
initially drew up a list of 14 general areas to cover in this series, 
but later found that there are several major areas of modem 
cardiology, prominently molecular cardiology, in which the 
truly landmark articles have, alas, not yet been published in 
JACC. Therefore, the working group decided not to categorize 
by subject, but instead, to concentrate on the most important 
articles. 
The working group, a task force of the Subcommittee for the 
Commemoration f the ACC 50th Anniversary, owes a great 
deal to Ms. May A. Roustom and the efficient and tireless staff 
at Heart House for facilitating this project. We also wish to 
thank all who suggested articles and, most important, the 
authors who prepared reviews for their willingness to contribute 
their time and wisdom. 
Influential Articles in JACC Working Group 
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national concern. To better define the prevalence, demog- 
raphy and correlates of atherosclerosis required a compre- 
hensive pidemiologic survey of the disorder and associated 
or causative factors. Initially, it was thought that a single 
general etiology for atherosclerofic disease would be found; 
it is now clear that atherosclerosis and its complications 
must be considered as both polygenic and multifactorial. 
In a recent article rifled "Unlocking the Heart's Secrets," 
U.S. News and World Report (Sept. 7, 1998) (2) declared, 
"The Frarningham Heart Study is one of the most cele- 
brated works of epidemiology in the history of medicine." 
Dr. M. E. DeBakey commented, "It has set the model in 
epidemiology . . . .  It is truly one of the great studies of this 
century." 
It is generally agreed that the Framingham Heart Study 
has provided information critical to the recognition and 
management of atherosclerosis and its secular causes and 
complications. In the near future, new knowledge of the 
polygenic background of these vascular disorders and their 
fundamental biology, identification of "genetic" protection 
against, or propensity for, those biologic mechanisms and 
responses that underlie arterial wall pathology, and throm- 
botic responses to injury will provide a further paradigm 
shift in the understanding of atherosclerosis. 
Regrettably, common use of terms from authoritative lay 
dictionaries without regard for actual medical definitions 
has irrevocably established the terms "prevention," "prima- 
ry," and "secondary" in this field. "Prevention," for example, 
is defined in Webster (3) as follows: "1. To keep from 
occurring, 2. to stop from doing something, 3. to interpose 
a hindrance." To "prevent," therefore, is to stop something 
by forestalling action and rendering it impossible. This 
desired outcome--the limination of atherosclerotic vascu- 
lar disease by current strategies--is currently improbable in 
all but a few individuals who are genetically fortunate. In 
contrast, to "hinder" is to hold back by delaying or stopping 
progress or action; this term is more appropriate for current 
accomplishments. True prevention will require solution of 
the second component of the problem--the genetic predis- 
position or susceptibility to vascular disease or the protec- 
tion against the influence of secular factors known and 
unknown. Genetics govern cellular and system responses. 
Some persons may have "healthy" endothelium, and others 
may have a thrombotic overresponse. These opposite and 
complex mechanisms are essential targets for future research 
that might permit true prevention. 
THE FRAMINGHAM HEART STUDY 
For the first collection of community cohort information, 
1,980 men and 2,421 women were enrolled between 1948 
and 1951 (4). Historical data collected sought evidence for 
prior coronary heart disease (CHD) and specifics regarding 
blood pressure elevation, smoking habits and alcohol use 
were also included. A physical examination was conducted 
and an electrocardiogram obtained. Laboratory values, in- 
cluding serum lipoprotein cholesterol levels, were obtained 
by standardized methods, but values of high-density li- 
poprotein cholesterol (HDL-C) were not measured in all 
subjects. The resulting seminal article, "Factors of Risk in 
the Development of Coronary Heart Disease: Six-Year 
Follow-up Experience. The Framingham Heart Study" was 
published in the Annals of Internal Medicine in 1961. From 
this article, the concept of "risk factors" was elaborated upon 
and the development of a cardiovascular risk profile 
emerged (5-7). 
The Framingham Offspring Study. The report, "Preva- 
lence of Coronary Heart Disease in the Framingham 
Offspring Study: Role of Lipoprotein Changes," reproduced 
in abstract form earlier in this article, first appeared in the 
October 1980 issue of the American Journal of Cardiology (8). 
The cohort subjects consisted of the original 1,980 men and 
2,421 women entered in the Framingham Heart Study 
between 1948 and 1951. The offspring subjects consisted of 
1,719 men and 1,768 womenmwho were either genetic or 
adoptive offspring, or spouses of offspring of the original 
cohort. The HDL-C, an important variable not previously 
measured in many of the cohort group, and body weight and 
estimates of obesity were included. A greater proportion of 
younger men and women were represented in the offspring 
group. Of  the men, 43 had clinically recognized CHD at 
enrollment, as did 11 of the women. The crude rate of 
clinical CHD (per 1,000) for the offspring slightly exceeded 
that of the cohort--25 versus 18 for men and 7 versus 6 for 
women. As in the cohort study, the prevalence of CHD was 
strongly associated with age, gender, smoking, systolic 
blood pressure and total cholesterol (T-C) and low-density 
lipoprotein cholesterol (LDL-C) levels, thus validating the 
prior conclusions. In addition, a decreased level of HDL-C,  
especially in women, and an increased T -C/HDL-C ratio 
were also found to be strongly associated with increased risk. 
Interestingly, the level of very low-density lipoprotein cho- 
lesterol (VLDL-C) did not prove to be an independent risk. 
The finding of several risk factors in an individual subject 
was of particular significance in regard to overall or total 
individual risk for an adverse vascular event. The 12-year 
incidence of CHD in the Framingham offspring was re- 
ported in 1991 (9). Over the 12 years, 156 of the 1,663 men 
and 55 of the 1,714 women developed clinical CHD. Once 
again, CHD was significantly associated with age, gender, 
LDL-C levels, lower HDL-C levels and number of ciga- 
rettes smoked. Fasting glucose and LDL-C levels were 
highly associated with CHD in men but were borderline in 
women, whereas triglyceride and VLDL-C levels were not 
significantly associated with CHD after adjustment for 
HDL-C  and blood glucose. Remarkably, a statistically 
significant association between systolic blood pressure and 
coronary artery disease (CAD) was not demonstrated in
either men or women. Hypertension control had increased, 
cigarette smoking had declined uring the 1970s and 1980s 
and the potential for large reductions in blood cholesterol 
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levels was evident. The longitudinal aspect of the study of 
CHD events again underscored the importance oflipids and 
fostered programs to optimize both T-C and LDL-C levels. 
Epidemiology as a science basic to atherosderosis and 
CAD. Although most reports concerning the Framingham 
Heart Study have appeared in general medical and epide- 
miologic journals, Dr. William B. Kannel's Bishop Lecture, 
"Contribution of the Framingham Study to Preventive 
Cardiology," published in the Journal of tbe~dmerican College 
of Cardiology in 1990 (10), amply justified the epidemiologic 
approach to the study of such a multifactorial disorder. 
Reliable, objective information was now available regarding 
the incidence of cardiovascular disease and the importance 
,~f risk factors in predicting the propensity for adverse 
clinical events. 
Influence. This series of seminal reports (4-10) resulted in 
the establishment of the Lipid Research Clinic project (11) 
a,ld the National Cholesterol Education Program (12,13), 
which have focused on the optimal management of athero- 
sclerosis and CAD. The Framingham data have served 
many nations and remain the bedrock of programs world- 
wide. Unfortunately, control oflipids by diet alone has not 
proven satisfactory in U.S. patients (14,15). This finding has 
fi-,stered the development of pharmaceuticals to effectively 
ai~d safely reduce T-C and LDL-C (16). Prior concern 
regarding potential adverse clinical outcomes of lowered 
T-C has not been substantiated (17). Randomized clinical 
trials (RCTs) using drugs of the hepatic hydroxymethyl 
glutaryl coenzyme A (HMG Co-A) reductase-inhibitor 
class ("statins") have shown significant lowering of T-C and 
LDL-C to be associated with a striking reduction in CAD 
t'vents in men and women following acute myocardial 
.lfarction (AMI) (18), men at greatly increased risk but 
without prior AMI (19), men and women with normal T-C 
levels post-AMI (20) and in a general population not at 
iilcreased risk (21). However, RCTs serve only to distribute 
risk equally between enrolled test and control arms. Within 
each arm, the subjects are far from homogeneous, with 
individual risks ranging from negligible to inevitable. An 
RCT will demonstrate only an "average" outcome and 
whether any change between the means in placebo and 
treated groups is not due to chance alone. This "average" is
due to a shift in the distribution of individual outcomes, and 
it is not illogical to postulate that this shift must occur in 
individuals within a cohort who are at greatest individual 
risk. Hence, clinical trial data must be reassessed with care 
to ensure that only those who can benefit receive treatment 
and that resources are not expended by "treating" persons 
who cannot benefit. Subpopulafion analysis of risk is now 
critical, if for no other reason than to minimize inclusion of 
those at minimal risk for an adverse vent. 
The 27th Bethesda Conference of the American CoUege 
of Cardiology (22), co-chaired by Drs. Thomas S. Pearson 
and Valentin Fuster, underscored the importance of 
"matching the intensity of treatment with the hazard for 
CAD events." This principle is imperative because the cost 
of general application of statin therapy for all subjects at any 
level of risk would be prohibitive (23). 
Dr. Peter Wilson has summarized the secular trends in 
cardiac risk factor levels from the Framingham experience 
(24). Mean systolic blood pressures were lower in the 
second-generation subjects, and the proportion of persons 
on blood pressure therapy increased in both sexes. Current 
cigarette smoking decreased, and there was only a slight 
increase in mean body mass levels. Whereas T-C and 
LDL-C levels were lower in the Framingham offspring, 
there was no significant difference between the cohort and 
the offspring groups in triglyceride and HDL-C  levels. 
Although coronary death rates have declined greatly in the 
Framingham Study results and in the U.S. since 1970, a 
commensurate d crease in levels of coronary risk factors is 
less apparent. A significant part of this decline is due not to 
risk factor reduction but to treatment aimed at correcting a
specific feature in an individual patient, i.e., the use of 
thrombolysis, coronary artery bypass graft (CABG) proce- 
dures and, more recently, coronary angioplasty with or 
without stent placement. Patients with any CHD events or 
cardiac symptoms now undergo careful scrutiny, and when 
secular isk factors are present (as they usually are), these 
patients are targeted for prompt and effective treatment. 
Again, the motivation o£ physicians and patients is strik- 
ingly different after such a wake-up call. 
Overall risk estimation. It is now incontrovertible that 
blood pressure levation, cigarette smoking, T-C levels and 
their subfractions and the presence of diabetes or insulin 
resistance combined with nonmodifiable factors of age and 
gender can provide in numerical terms a probability for 
CHD events over a follow-up interval of several years. A 
scoring sheet that allows physicians to estimate CHD risk 
has now been proposed (25). Although such estimates may 
be less than precise, they serve as excellent guidelines and 
may motivate patients at risk for CAD to adopt a healthy 
lifestyle and, when necessary, to receive appropriate medi- 
cation. If, indeed, the intensity of management is to relate to 
the risk for coronary disease vents, then a best numerical 
estimate of risk is an essential starting place. 
I believe that such a risk score should be included in the 
chart of every patient; these scores would permit implemen- 
tation of appropriate preventive strategies based on each 
patient's needs. For the future, it is reasonable to anticipate 
major additions to enhance the precision and utility of the 
Framingham risk estimate. Framingham fundamentally ob- 
served patients in a free-living environment. The manage- 
ment objective was, and is, primary prevention--namely, to 
hinder the development of non- or preclinical atheroscle- 
rotic disease and its complications. It is clear, however, that 
the Framingham risk factors play an even more important 
role in the management of existing coronary disease--- 
designated as secondary prevention--where the 10-year isk 
is automatically doubled or quadrupled. To date, the most 
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cost-effective application of risk factor management has 
been in secondary prevention. 
Accrual of carefully collected clinical detail about each 
patient, as well as the selected use of more advanced 
diagnostic techniques when required, can establish confi- 
dence in the degree of risk estimation eeded for clinical 
decision making regarding treatment. Studies may include 
stress testing (with or without radionucleide or echocardio- 
graphic imaging), blood viscosity and white cell count, 
coronary calcification score, perhaps fibrinogen and homo- 
cysteine levels, and, in the future, identification of strong 
genetic markers. Addition of these variables will refine the 
accuracy of risk factor determinations and define more 
exactly for which individuals within a certain population 
specific therapy can be economically justified. Treatment 
defined on the basis of lipoproteins alone can be grossly 
misleading. 
Impact of the Framingham Heart Study. Dr. Kanners 
Bishop Lecture (10) summarized the contribution of the 
Framingham Heart Study to preventive cardiology. The 
association with frank diabetes or impaired glucose toler- 
ance was greater in women but was also found to be highly 
dependent on coe~sting cardiovascular risk factors, includ- 
ing lipid levels. Fibrinogen is another major and indepen- 
dent atherogenic risk factor that may be involved in both 
atherogenesis and thrombogenesis. The doubling of fibrin- 
ogen levels from the lowest to the highest may double the 
12-year ate of CHD events. The Framingham study found 
a protective ffect at low or moderate levels of exercise, 
dispelling the previously held opinion that it was necessary 
to exercise vigorously. Particularly in older individuals, 
exercise at a moderate l vel seemed to reduce the adverse 
CHD event rate by almost half over a 14-year interval. 
Although weight gain was found to make a modest inde- 
pendent contribution to CHD incidence, it, of course, 
promotes all of the other major atherogenic risk factors, 
including dyslipidemia, hypertension, impaired glucose tol- 
erance, hyperglycemia and elevated fibrinogen; in addition, 
it is associated with a more sedentary lifestyle. In Dr. 
Kanners 1994 report (26), "Clinical Misconceptions Dis- 
pelled by Epidemiological Research," he proposed that, 
even with current knowledge, a cardiovascular event must be 
regarded as a medical failure rather than the first indication 
of a treatment eed. In most chronic ongestive heart failure 
(CHF) patients, the primary causes of CHF are hyperten- 
sion and ischemic heart disease. The incidence of CHF 
seems to be increasing, coincident with increased immediate 
survival after AMI as a consequence of newer therapies, 
including thrombolysis and primary angioplasty. The CHF 
outcomes remain unsatisfactory in terms of morbidity and 
mortality and now represent a great personal and economic 
burden on the individual and on society. Because revascu- 
larization does not decrease the incidence of AMI (27), lipid 
lowering with this purpose in mind is an idea whose time for 
testing has come. Epidemiologic studies have demonstrated 
the relationship between peripheral arterial disease (PAD) 
and cardiovascular disease. Not unexpectedly, CHD is the 
most common immediate cause of death in PAD patients. 
The same primary risk factors associated with CHD also 
predict intermittent claudication and include systolic blood 
pressure level, presence of diabetes, cigarette smoking, 
elevated cholesterol and left ventricular hypertrophy. In 
PAD, the most powerful risk factors are cigarette smoking 
and diabetes. 
Some, now mindful of the potentially dramatic hanges 
in management that have been suggested by new findings 
on the fundamental processes of atherosclerosis, might 
debate Dr. Kannell's tatement, "Epidemiology has emerged 
as the basic science for preventive cardiology" (26). How- 
ever, the significant progress that has been attained to date 
in the management of vascular diseases is, nonetheless, 
based on the insights provided by the Framingham Heart 
Study investigators. 
In spite of current rends toward, and increasing eneral 
dependence on, drug therapy, as well as lack of confidence 
in the U.S. in dietary approaches alone (19), recent data 
from eastern Finland (28) suggest that programs of com- 
munity education and the availability of low-fat food have 
caused a significant reduction in lipoprotein risk factors. 
This Finnish study underscores the importance of cost 
considerations in the widespread application of all new 
strategies. Therapy for a11 patients at any risk with statins is 
cost prohibitive, even in the so-called eveloped countries. 
CONCLUSIONS 
The initiation of the Framingham Heart Study and the 
offspring study were true milestones in the history of 
cardiology--a conceptual leap forward. The resulting re- 
ports have provided a fundamental pproach to the man- 
agement of atherosclerotic disease. We who are involved in 
clinical care and clinical decision-making for individual 
patients will forever emain in debt to the many outstanding 
and dedicated scientists responsible for the purposeful 
design, effective data collection and responsible interpreta- 
tion of the secular factors that underlie atherosclerotic 
vascular diseases. 
Reprint requests and correspondence: Dr. H. J. C. Swan, 250 
North San Rafael Avenue, Pasadena, CA 91105. 
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